Lobe Sciences Ltd. is a biopharmaceutical company focused on developing psychedelic compounds to enhance mental health. While it boasts a strong liquidity position with a current ratio of 2.87, indicating good short-term financial health, its negative return on assets (ROA) of -12.3% raises concerns about profitability. The low market cap of $10.79M and stagnant price suggest potential undervaluation, but this may also reflect investor skepticism regarding its business model and future growth prospects. Overall, while the company has promising research avenues, financial performance remains a critical concern.
Loading financial metrics...
Company posted a loss of $-5.3M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.0M over the last year.
Fortress balance sheet: cash covers total debt 3.2×, providing significant financial flexibility.
Excellent liquidity with current ratio of 2.9x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (May 31, 2025)